An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.
Patients with hidradenitis suppurativa (HS) are at significantly greater risk of myocardial infarction (MI), but not cerebrovascular accident (CVA) or peripheral vascular disease (PVD), according to study findings published in Archives of Dermatological Research.
Characterized by its chronic and relapsing disease burden, HS is a skin condition of the hair follicles that is commonly associated with metabolic and cardiovascular comorbidities such as type 2 diabetes, dyslipidemia, obesity, and hypertension.
“Due to the strong association of HS with metabolic syndrome, which is often defined as a combination of glucose dysregulation, hypertension, obesity, and dyslipidemia, the potential of HS being associated with atherothrombotic risk such as MI, stroke, and peripheral arterial disease of the lower extremities, has been explored,” said the study authors.
“Although the association of HS with a higher risk of adverse cardiovascular events has been previously explored, information is still sparse and not well established.”
Seeking to assess the risk and prognostic outcomes of MI, CVA, and PVD in patients with HS, researchers conducted a population-based retrospective cohort study using the computerized database of Clalit Health Services (CHS), the largest managed care organization in Israel.
Participants with HS (n = 6779) were compared with age-, sex-, and ethnicity-matched control subjects (n = 33,260) on the incidence of MI, CVA, and PVD, which was expressed as the number of events per 1000 person-years. The cumulative survival of patients with HS with and without MI, CVA, and PVD diagnosis was also calculated using Kaplan–Meier method and compared via stratifed log-rank test.
To control for putative confounders, outcome measures were adjusted for cardiovascular risk factors, including body mass index (BMI), diabetes mellitus, hyperlipidemia, hypertension, and smoking.
Among the study cohort, mean BMI and the prevalence of smoking, diabetes mellitus, hyperlipidemia, and hypertension were significantly greater in patients with HS than in controls. Overall incidence rates of MI, CVA, and PVD were estimated at 2.9 (2.3-3.4), 1.3 (0.9-1.7), and 0.8 (0.6-1.1) per 1000 person-year, respectively, with corresponding estimates in the control group calculated at 1.8 (1.6-2.0), 1.2 (1.1-1.4), and 0.5 (0.4-0.7) per 1000 person-year, respectively.
After stratifying for all potential confounders, patients with HS were found to be at an increased risk of developing MI (fully-adjusted HR, 1.33; 95% CI, 1.04-1.68; P = .021). Conversely, risk of CVA (fully-adjusted HR, 0.82; 95% CI, 0.59-1.14; P = .245) and PVD (fully-adjusted HR, 1.22; 95% CI, 0.80-1.87; P = .355) was comparable between patients with HS and controls.
Regarding cumulative survival analyses, an increased risk of all-cause mortality was observed among patients with HS and comorbid MI (HR, 12.56; 95% CI, 7.59-20.80; P < .001), CVA (HR, 13.33; 95% CI, 7.29-24.37; P < .001), and PVD (HR, 7.11; 95% CI, 2.61-19.32; P < .001), compared with patients with HS without these comorbidities.
“It is essential for practicing dermatologists to counsel patients with HS regarding this association so patients can best mitigate their own individual cardiovascular and metabolic risk factors, such as ensuring their diabetes is well controlled, attempting smoking cessation, and emphasizing healthy lifestyle modifcations,” wrote the researchers.
They concluded that further research is warranted to investigate these significant associations and their underlying pathogenic mechanisms.
Reference
Kridin K, Valido K, Cohen JM, Cohen AD. Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population‑based study. Arch Dermatol Res. Published online July 23, 2022. doi:10.1007/s00403-022-02369-5
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More